$CUE
Cue Biopharma, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022014747 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $68.00K $26.00K $1.000M
YoY Change -97.16% -99.05% -35.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.528M $3.782M $5.156M
YoY Change -13.95% -11.12% 21.89%
% of Gross Profit
Research & Development $7.571M $9.592M $10.08M
YoY Change -31.15% 9.47% 2.71%
% of Gross Profit
Depreciation & Amortization $198.0K $212.0K $220.0K
YoY Change -37.34% -8.23% 0.92%
% of Gross Profit
Operating Expenses $11.10M $13.12M $15.24M
YoY Change -27.99% 0.57% 8.29%
Operating Profit -$11.03M -$13.09M -$14.24M
YoY Change -15.26% 27.05% 13.74%
Interest Expense $124.0K $206.0K $25.00K
YoY Change 396.0%
% of Operating Profit
Other Income/Expense, Net $76.00K -$118.0K -$17.00K
YoY Change 204.0% -591.67% -230.77%
Pretax Income -$10.96M -$13.21M -$14.26M
YoY Change -15.69% 28.49% 13.95%
Income Tax
% Of Pretax Income
Net Earnings -$10.96M -$13.21M -$14.26M
YoY Change -15.69% 28.49% 13.99%
Net Earnings / Revenue -16110.29% -50800.0% -1425.5%
Basic Earnings Per Share -$0.31 -$0.37 -$0.44
Diluted Earnings Per Share -$0.31 -$373.6K -$436.8K
COMMON SHARES
Basic Shares Outstanding 35.38M 35.37M 33.01M
Diluted Shares Outstanding 35.38M 35.36M 32.64M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.18M $66.13M $67.93M
YoY Change -12.49% -10.54% -7.33%
Cash & Equivalents $29.73M $66.13M $67.93M
Short-Term Investments $29.46M $0.00 $0.00
Other Short-Term Assets $1.721M $2.142M $7.095M
YoY Change -7.02% -44.41% 162.78%
Inventory
Prepaid Expenses
Receivables $796.0K $736.0K $925.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $61.70M $69.00M $75.95M
YoY Change -12.18% -13.4% -1.88%
LONG-TERM ASSETS
Property, Plant & Equipment $1.642M $1.765M $1.918M
YoY Change -71.23% -31.0% -31.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $131.0K $134.0K $137.0K
YoY Change -95.5% -95.4% -95.28%
Total Long-Term Assets $14.60M $15.75M $14.76M
YoY Change 69.37% 57.53% 30.59%
TOTAL ASSETS
Total Short-Term Assets $61.70M $69.00M $75.95M
Total Long-Term Assets $14.60M $15.75M $14.76M
Total Assets $76.30M $84.75M $90.70M
YoY Change -3.26% -5.49% 2.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.045M $1.568M $2.617M
YoY Change -17.21% -47.59% 4.68%
Accrued Expenses $3.879M $3.559M $3.406M
YoY Change -49.11% -48.25% -51.34%
Deferred Revenue
YoY Change
Short-Term Debt $37.00K $0.00 $0.00
YoY Change
Long-Term Debt Due $1.000M
YoY Change
Total Short-Term Liabilities $10.22M $8.323M $11.41M
YoY Change -33.43% -50.08% -31.26%
LONG-TERM LIABILITIES
Long-Term Debt $8.993M $9.913M $9.861M
YoY Change
Other Long-Term Liabilities $6.321M $6.757M $4.759M
YoY Change 7492.13% 98.29%
Total Long-Term Liabilities $8.993M $9.913M $9.861M
YoY Change 11038.2% 310.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.22M $8.323M $11.41M
Total Long-Term Liabilities $8.993M $9.913M $9.861M
Total Liabilities $25.54M $24.99M $26.03M
YoY Change 66.3% 49.11% 36.29%
SHAREHOLDERS EQUITY
Retained Earnings -$235.9M -$224.9M -$211.7M
YoY Change 24.75%
Common Stock $286.7M $284.7M $276.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.76M $59.76M $64.67M
YoY Change
Total Liabilities & Shareholders Equity $76.30M $84.75M $90.70M
YoY Change -3.26% -5.49% 2.26%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$10.96M -$13.21M -$14.26M
YoY Change -15.69% 28.49% 13.99%
Depreciation, Depletion And Amortization $198.0K $212.0K $220.0K
YoY Change -37.34% -8.23% 0.92%
Cash From Operating Activities -$6.871M -$12.85M -$11.57M
YoY Change 3.68% 31.57% -1.88%
INVESTING ACTIVITIES
Capital Expenditures -$78.00K -$65.00K $27.00K
YoY Change 500.0% -74.0% -95.83%
Acquisitions
YoY Change
Other Investing Activities -$29.44M $3.000K $0.00
YoY Change -1472200.0% -84.21% -100.0%
Cash From Investing Activities -$29.52M -$62.00K -$27.00K
YoY Change 268263.64% -73.16% -100.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $191.0K
YoY Change 124.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -9.000K 11.11M 15.16M
YoY Change -102.56% 4.11% 1717.27%
NET CHANGE
Cash From Operating Activities -6.871M -12.85M -11.57M
Cash From Investing Activities -29.52M -62.00K -27.00K
Cash From Financing Activities -9.000K 11.11M 15.16M
Net Change In Cash -36.40M -1.801M 3.556M
YoY Change 478.97% -367.21% -321.01%
FREE CASH FLOW
Cash From Operating Activities -$6.871M -$12.85M -$11.57M
Capital Expenditures -$78.00K -$65.00K $27.00K
Free Cash Flow -$6.793M -$12.78M -$11.60M
YoY Change 2.71% 34.35% -6.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
128000
dei Entity Central Index Key
EntityCentralIndexKey
0001645460
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38327
dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2680
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35381743
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66126000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64371000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
736000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3142000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2142000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
69004000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68468000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1765000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2112000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9899000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9810000
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3797000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2721000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
134000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2022Q2 us-gaap Assets
Assets
84749000
CY2021Q4 us-gaap Assets
Assets
83401000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1568000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2591000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3559000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4620000
CY2022Q2 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
0
CY2021Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
645000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3196000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4932000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8323000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12788000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6757000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5121000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9913000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q2 us-gaap Liabilities
Liabilities
24993000
CY2021Q4 us-gaap Liabilities
Liabilities
17909000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35381743
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35381743
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32202496
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32202496
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
35000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
284630000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
262906000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-224909000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197446000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59756000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84749000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83401000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2739000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1026000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4291000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3782000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4280000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8938000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8535000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9592000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8762000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19675000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18577000
CY2022Q2 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
258000
CY2021Q2 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
258000
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
13116000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
13042000
us-gaap Operating Expenses
OperatingExpenses
28355000
us-gaap Operating Expenses
OperatingExpenses
27112000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13090000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10303000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27329000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22821000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
88000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
24000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
96000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
37000
CY2022Q2 us-gaap Interest Expense
InterestExpense
206000
CY2021Q2 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
230000
us-gaap Interest Expense
InterestExpense
0
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-118000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-134000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13208000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10279000
us-gaap Net Income Loss
NetIncomeLoss
-27463000
us-gaap Net Income Loss
NetIncomeLoss
-22784000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13208000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10279000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27463000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22791000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35357343
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31233794
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34005410
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30834522
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
69669000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10356000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2854000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
310000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10279000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
72910000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
64673000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5982000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2309000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13208000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59756000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
78911000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10357000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5290000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1228000
us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
85000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-7000
us-gaap Net Income Loss
NetIncomeLoss
-22784000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
72910000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16598000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5320000
cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-191000
us-gaap Net Income Loss
NetIncomeLoss
-27463000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59756000
us-gaap Profit Loss
ProfitLoss
-27463000
us-gaap Profit Loss
ProfitLoss
-22784000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
518000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
632000
us-gaap Share Based Compensation
ShareBasedCompensation
5320000
us-gaap Share Based Compensation
ShareBasedCompensation
5290000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
169000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
2252000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
258000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
19000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-5000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
43000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2407000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
487000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1268000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2787000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-250000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-1075000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-47000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1023000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
922000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1062000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-784000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-645000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-1726000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-100000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2272000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24421000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21565000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
900000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
19000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
0
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-10000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-89000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9119000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
16598000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
10357000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1228000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
142000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
191000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
85000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26265000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11500000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1755000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-946000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75016000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66276000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74070000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
206000
us-gaap Interest Paid Net
InterestPaidNet
214000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9057000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
cue Operating Lease Modification
OperatingLeaseModification
7119000
cue Operating Lease Modification
OperatingLeaseModification
0
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66126000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7102379
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6750493
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52485000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52509000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52485000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52509000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
816000
CY2022Q2 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2021Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q2 cue Accretion Of Final Payment
AccretionOfFinalPayment
43000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-130000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
9913000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5633000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5556000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3868000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3444000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1765000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2112000
CY2022Q2 us-gaap Depreciation
Depreciation
212000
CY2021Q2 us-gaap Depreciation
Depreciation
231000
us-gaap Depreciation
Depreciation
432000
us-gaap Depreciation
Depreciation
449000
cue Amortization Of Trademark
AmortizationOfTrademark
6000
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
80000
cue Amortization Of Trademark
AmortizationOfTrademark
6000
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
177000
CY2023Q1 cue Prepayment Premium Rate
PrepaymentPremiumRate
0.0300
CY2024Q1 cue Prepayment Premium Rate
PrepaymentPremiumRate
0.0200
CY2025Q1 cue Prepayment Premium Rate
PrepaymentPremiumRate
0.0100
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
43000
us-gaap Interest Expense Other
InterestExpenseOther
43000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4000000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y9M7D
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16175000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
142000
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0256
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.921
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.957
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0061
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0131
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.978
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.009
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5654168
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y5M23D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.06
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
163814
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.75
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6306354
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M3D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4055849
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
0
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
21198000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
122500
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
991000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.43
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4056000
CY2022Q2 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
3.77
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2309000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2854000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-5320000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5290000
cue Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Of Common Stock
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueOfCommonStock
2.49
CY2015Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1500
CY2022Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2015-06-15
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.70
CY2015Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P7Y
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
851969
cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
9549
cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
51562
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1500
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
789358
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2500000
cue Milestone Payments Received
MilestonePaymentsReceived
2800000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2500000
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1250000
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
Upon execution of the Laboratory and Office Lease, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. The Company also prepaid seven and one-half months’ rent pursuant to an amendment to the lease agreement executed on June 18, 2018. These amounts were recorded to deposits and prepaid expenses, respectively, at December 31, 2018
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
128000
CY2022Q2 us-gaap Security Deposit Liability
SecurityDepositLiability
803000
CY2021Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
803000
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1584000
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3255000
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2742000
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2679000
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
783000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11043000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1091000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9952000
CY2022Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1105000
CY2021Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1223000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2439000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2445000000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
2272000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1105000
us-gaap Operating Lease Cost
OperatingLeaseCost
2439000
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M14D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M14D

Files In Submission

Name View Source Status
0000950170-22-014747-index-headers.html Edgar Link pending
0000950170-22-014747-index.html Edgar Link pending
0000950170-22-014747.txt Edgar Link pending
0000950170-22-014747-xbrl.zip Edgar Link pending
cue-20220630.htm Edgar Link pending
cue-20220630.xsd Edgar Link pending
cue-20220630_cal.xml Edgar Link unprocessable
cue-20220630_def.xml Edgar Link unprocessable
cue-20220630_htm.xml Edgar Link completed
cue-20220630_lab.xml Edgar Link unprocessable
cue-20220630_pre.xml Edgar Link unprocessable
cue-ex10_1.htm Edgar Link pending
cue-ex10_2.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img52975889_0.jpg Edgar Link pending
img53899410_0.jpg Edgar Link pending
img76100411_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending